Cell and Gene Therapy Consumables Market, by Product Type (Kits and Buffers, Culture Medium, Cryopreservation Media, Diagnostic Assay, and Others), by Application/Therapeutics (Cardiovascular, Dermatology, Endocrine & Metabolic, Gastroenterology, Hematology & Oncology, Obstetrics, Critical Care, Immunology, Neuroscience, Respiratory, Urology, and Others), by Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027

Report ID :AMI-332 | Category : Healthcare | Published Date : January, 2020 | Pages : 702 | Format :PDF

Market Overview/Industry Trends:

Cell and gene therapy involves the use of cells and genes for the treatment of diseases which are caused by mutations or errors in genes leading to a loss or change of function of RNA or protein molecules. Cell therapy involves the transfer of live cells with the appropriate tissue or organ restoration function into the patient, whereas gene therapy involves the transfer of genetic material, usually in a carrier or vector and the uptake of the gene into appropriate body cells. Cell therapy treats diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body while gene therapy focuses on the treatment of diseases by replacing, inactivating or introducing genes into cells, either in vivo ex vivo. Some of the factors characterizing the market growth are growing prevalence of target diseases (cardiovascular diseases, cancer, metabolic disorders, etc.), increasing awareness regarding gene therapy, rising demand for innovative medicines, introduction of effective guidelines regarding cell and gene therapies, and increasing funding for R&D activities. On the contrary, high costs associated with the treatment, unwanted immune responses from these therapy medicines, and difficulties in conducting randomized controlled trials (RCTs) for these therapies are anticipated to hinder the cell and gene therapy consumables market growth over the forecast period.

Worldwide rising prevalence of targeted diseases such as cardiovascular diseases (CVDs), cancer, impaired metabolic pathways, inherited blindness, metabolic disorders, and protein related disorders are likely to propel the demand for cell and gene therapy products during the assessment period. For instance, as per the data published by World Health Organization (WHO), in 2018, the global cancer burden was 18.1 million new cases and 9.6 million deaths as compared to 12.7 million new cases of cancer and the 7.6 million cancer deaths worldwide during 2008. The WHO reported that cardiovascular diseases are the major cause of death worldwide, causing an estimated 17.9 million deaths every year. Thus, this is fostering the demand for cell and gene therapy consumables market. In terms of revenue, the global cell and gene therapy consumables market was estimated to be US$ 641.22 Mn in 2018 and is expected to reach US$ 6,999.35 Mn by 2027 growing at a CAGR of 30.43% over the forecast period. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.

Cell and Gene Therapy Consumables Market Revenue & Forecast, (US$ Million), 2015–2027

Product Type Outlook:

The kits and buffers segment accounted for substantial share of cell and gene therapy consumables market in 2018 owing to its comparatively higher adoption and repetitive purchase during cell and gene therapies. Technological developments in kits for example, GE Healthcare offers disposable or single-use kits and bioreactor bags which support automated and functionally closed cell processing across the workflow are supporting the dominance of the segment. Some of the commercially available kits are Autologous and Allogeneic Cell Therapy Kits and Nontherapeutic Research and Development Kits (Akron Biotech) and RoboSep Buffer (STEMCELL Technologies Inc.).

Application/Therapeutics Outlook:

The cardiovascular segment dominated the cell and gene therapy consumables market in 2018 and is expected to maintain its status quo over the review period due to globally rising burden of CVDs along with growing demand for cell and gene therapy to treat cardiovascular diseases, namely, coronary artery disease (CAD) or coronary heart disease (CHD), stroke, cardiac arrhythmias, and hypertension. The WHO stated that coronary heart disease is now the leading cause of death worldwide. About 3.8 million men and 3.4 million women die each year from coronary heart disease across the world. The most advances in medicine such as the use of stem cell and gene therapy to repair all forms of acute and chronic illness are about to nurture the market growth in the near future.The critical care segment is expected to exhibit comparatively higher CAGR over the forecast period on account of rising use of gene therapy in critical care medicines to treat several conditions such as severe sepsis and the acute respiratory distress syndrome (ARDS), including acute lung injury (ALI).

Competitive Landscape:

The report provides both qualitative and quantitative research of cell and gene therapy consumables market as well as provides comprehensive insights and development methods adopted by the prominent market players. Some of the key market participants in the cell and gene therapy consumables market are Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook Medical, Dendreon Pharmaceuticals LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc, Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, ViroMed Co., Ltd., and Vitrolife. These players have adopted growth strategies such as new product launches, partnerships, collaborations, mergers and acquisitions, and joint ventures (JVs) in order to gain a competitive advantage. For instance, in May 2019, General Electric launched chronicle automation software for cell therapy. In October 2018, bluebird bio, Inc. received an approval from European Medicines Agency (EMA) for its investigational LentiGlobin gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT).

For each company, the report studies their global presence, competitors and product offerings, among others.

Click on image to enlarge

Global Cell and Gene Therapy Consumables Market:

By Product Type
- Kits and Buffers
- Culture Medium
  - Natural Media
    - Plasma
    - Serum
    - Lymph
    - Human Placental Cord Serum
    - Amniotic Fluid
    - Others
  - Artificial Media
    - MEM
    - RPMI
    - PBS
    - DPBS
    - HBSS
    - EBSS
    - Others
- Cryopreservation Media
- Diagnostic Assay
- Others
By Application/Therapeutics
- Cardiovascular
- Dermatology
- Endocrine and Metabolic
- Gastroenterology
- Hematology and Oncology
- Obstetrics
- Critical Care
- Immunology
- Neuroscience
- Respiratory
- Urology
- Others
By Geography
- North America
  - US
  - Canada
  - Mexico
  - Rest of North America
- Europe
  - France
  - UK
  - Spain
  - Germany
  - Italy
  - Nordic Countries
    - Denmark
    - Finland
    - Iceland
    - Sweden
    - Norway
  - Benelux Union
    - Belgium
    - The Netherlands
    - Luxembourg
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - New Zealand
  - Australia
  - South Korea
  - Southeast Asia
    - Indonesia
    - Thailand
    - Malaysia
    - Singapore
    - Rest of Southeast Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East and Africa
  - Saudi Arabia
  - UAE
  - Egypt
  - Kuwait
  - South Africa
  - Rest of Middle East & Africa

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of Cell and Gene Therapy Consumables Market

6. Market Synopsis: Cell and Gene Therapy Consumables Market

7. Cell and Gene Therapy Consumables Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Cell and Gene Therapy Consumables Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Cell and Gene Therapy Consumables Market

7.6. Porter’s Five Force Analysis

7.7. PESTEL Analysis

8. Global Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

8.2. Global Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

8.2.1. Kits and Buffers

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2013 – 2018

8.2.1.3. Market Forecast, 2019 – 2027

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2013 – 2018

8.2.1.5.1.2. Market Forecast, 2019 – 2027

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2013 – 2018

8.2.1.5.2.2. Market Forecast, 2019 – 2027

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2013 – 2018

8.2.1.5.3.2. Market Forecast, 2019 – 2027

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2013 – 2018

8.2.1.5.4.2. Market Forecast, 2019 – 2027

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2013 – 2018

8.2.1.5.5.2. Market Forecast, 2019 – 2027

8.2.2. Culture Medium (Definition, Market Estimation and Penetration, 2013 – 2018, Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Natural Media, Artificial Media)

8.2.2.1. Natural Media

8.2.2.1.1. Plasma

8.2.2.1.2. Serum

8.2.2.1.3. Lymph

8.2.2.1.4. Human Placental Cord Serum

8.2.2.1.5. Amniotic Fluid

8.2.2.1.6. Others

8.2.2.2. Artificial Media

8.2.2.2.1. MEM

8.2.2.2.2. RPMI

8.2.2.2.3. PBS

8.2.2.2.4. DPBS

8.2.2.2.5. HBSS

8.2.2.2.6. EBSS

8.2.2.2.7. Others

8.2.3. Cryopreservation Media

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2013 – 2018

8.2.3.3. Market Forecast, 2019 – 2027

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2013 – 2018

8.2.3.5.1.2. Market Forecast, 2019 – 2027

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2013 – 2018

8.2.3.5.2.2. Market Forecast, 2019 – 2027

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2013 – 2018

8.2.3.5.3.2. Market Forecast, 2019 – 2027

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2013 – 2018

8.2.3.5.4.2. Market Forecast, 2019 – 2027

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2013 – 2018

8.2.3.5.5.2. Market Forecast, 2019 – 2027

8.2.4. Diagnostic Assay

8.2.4.1. Definition

8.2.4.2. Market Estimation and Penetration, 2013 – 2018

8.2.4.3. Market Forecast, 2019 – 2027

8.2.4.4. Compound Annual Growth Rate (CAGR)

8.2.4.5. Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2013 – 2018

8.2.4.5.1.2. Market Forecast, 2019 – 2027

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2013 – 2018

8.2.4.5.2.2. Market Forecast, 2019 – 2027

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2013 – 2018

8.2.4.5.3.2. Market Forecast, 2019 – 2027

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2013 – 2018

8.2.4.5.4.2. Market Forecast, 2019 – 2027

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2013 – 2018

8.2.4.5.5.2. Market Forecast, 2019 – 2027

8.2.5. Others

8.2.5.1. Definition

8.2.5.2. Market Estimation and Penetration, 2013 – 2018

8.2.5.3. Market Forecast, 2019 – 2027

8.2.5.4. Compound Annual Growth Rate (CAGR)

8.2.5.5. Regional Bifurcation

8.2.5.5.1. North America

8.2.5.5.1.1. Market Estimation, 2013 – 2018

8.2.5.5.1.2. Market Forecast, 2019 – 2027

8.2.5.5.2. Europe

8.2.5.5.2.1. Market Estimation, 2013 – 2018

8.2.5.5.2.2. Market Forecast, 2019 – 2027

8.2.5.5.3. Asia Pacific

8.2.5.5.3.1. Market Estimation, 2013 – 2018

8.2.5.5.3.2. Market Forecast, 2019 – 2027

8.2.5.5.4. Middle East and Africa

8.2.5.5.4.1. Market Estimation, 2013 – 2018

8.2.5.5.4.2. Market Forecast, 2019 – 2027

8.2.5.5.5. Latin America

8.2.5.5.5.1. Market Estimation, 2013 – 2018

8.2.5.5.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Product Type

9. Global Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

9.2.1. Cardiovascular

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2013 – 2018

9.2.1.3. Market Forecast, 2019 – 2027

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2013 – 2018

9.2.1.5.1.2. Market Forecast, 2019 – 2027

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2013 – 2018

9.2.1.5.2.2. Market Forecast, 2019 – 2027

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2013 – 2018

9.2.1.5.3.2. Market Forecast, 2019 – 2027

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2013 – 2018

9.2.1.5.4.2. Market Forecast, 2019 – 2027

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2013 – 2018

9.2.1.5.5.2. Market Forecast, 2019 – 2027

9.2.2. Dermatology

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2013 – 2018

9.2.2.3. Market Forecast, 2019 – 2027

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2013 – 2018

9.2.2.5.1.2. Market Forecast, 2019 – 2027

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2013 – 2018

9.2.2.5.2.2. Market Forecast, 2019 – 2027

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2013 – 2018

9.2.2.5.3.2. Market Forecast, 2019 – 2027

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2013 – 2018

9.2.2.5.4.2. Market Forecast, 2019 – 2027

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2013 – 2018

9.2.2.5.5.2. Market Forecast, 2019 – 2027

9.2.3. Endocrine and Metabolic

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2013 – 2018

9.2.3.3. Market Forecast, 2019 – 2027

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2013 – 2018

9.2.3.5.1.2. Market Forecast, 2019 – 2027

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2013 – 2018

9.2.3.5.2.2. Market Forecast, 2019 – 2027

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2013 – 2018

9.2.3.5.3.2. Market Forecast, 2019 – 2027

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2013 – 2018

9.2.3.5.4.2. Market Forecast, 2019 – 2027

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2013 – 2018

9.2.3.5.5.2. Market Forecast, 2019 – 2027

9.2.4. Gastroenterology

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2013 – 2018

9.2.4.3. Market Forecast, 2019 – 2027

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2013 – 2018

9.2.4.5.1.2. Market Forecast, 2019 – 2027

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2013 – 2018

9.2.4.5.2.2. Market Forecast, 2019 – 2027

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2013 – 2018

9.2.4.5.3.2. Market Forecast, 2019 – 2027

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2013 – 2018

9.2.4.5.4.2. Market Forecast, 2019 – 2027

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2013 – 2018

9.2.4.5.5.2. Market Forecast, 2019 – 2027

9.2.5. Hematology and Oncology

9.2.5.1. Definition

9.2.5.2. Market Estimation and Penetration, 2013 – 2018

9.2.5.3. Market Forecast, 2019 – 2027

9.2.5.4. Compound Annual Growth Rate (CAGR)

9.2.5.5. Regional Bifurcation

9.2.5.5.1. North America

9.2.5.5.1.1. Market Estimation, 2013 – 2018

9.2.5.5.1.2. Market Forecast, 2019 – 2027

9.2.5.5.2. Europe

9.2.5.5.2.1. Market Estimation, 2013 – 2018

9.2.5.5.2.2. Market Forecast, 2019 – 2027

9.2.5.5.3. Asia Pacific

9.2.5.5.3.1. Market Estimation, 2013 – 2018

9.2.5.5.3.2. Market Forecast, 2019 – 2027

9.2.5.5.4. Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2013 – 2018

9.2.5.5.4.2. Market Forecast, 2019 – 2027

9.2.5.5.5. Latin America

9.2.5.5.5.1. Market Estimation, 2013 – 2018

9.2.5.5.5.2. Market Forecast, 2019 – 2027

9.2.6. Obstetrics

9.2.6.1. Definition

9.2.6.2. Market Estimation and Penetration, 2013 – 2018

9.2.6.3. Market Forecast, 2019 – 2027

9.2.6.4. Compound Annual Growth Rate (CAGR)

9.2.6.5. Regional Bifurcation

9.2.6.5.1. North America

9.2.6.5.1.1. Market Estimation, 2013 – 2018

9.2.6.5.1.2. Market Forecast, 2019 – 2027

9.2.6.5.2. Europe

9.2.6.5.2.1. Market Estimation, 2013 – 2018

9.2.6.5.2.2. Market Forecast, 2019 – 2027

9.2.6.5.3. Asia Pacific

9.2.6.5.3.1. Market Estimation, 2013 – 2018

9.2.6.5.3.2. Market Forecast, 2019 – 2027

9.2.6.5.4. Middle East and Africa

9.2.6.5.4.1. Market Estimation, 2013 – 2018

9.2.6.5.4.2. Market Forecast, 2019 – 2027

9.2.6.5.5. Latin America

9.2.6.5.5.1. Market Estimation, 2013 – 2018

9.2.6.5.5.2. Market Forecast, 2019 – 2027

9.2.7. Critical Care

9.2.7.1. Definition

9.2.7.2. Market Estimation and Penetration, 2013 – 2018

9.2.7.3. Market Forecast, 2019 – 2027

9.2.7.4. Compound Annual Growth Rate (CAGR)

9.2.7.5. Regional Bifurcation

9.2.7.5.1. North America

9.2.7.5.1.1. Market Estimation, 2013 – 2018

9.2.7.5.1.2. Market Forecast, 2019 – 2027

9.2.7.5.2. Europe

9.2.7.5.2.1. Market Estimation, 2013 – 2018

9.2.7.5.2.2. Market Forecast, 2019 – 2027

9.2.7.5.3. Asia Pacific

9.2.7.5.3.1. Market Estimation, 2013 – 2018

9.2.7.5.3.2. Market Forecast, 2019 – 2027

9.2.7.5.4. Middle East and Africa

9.2.7.5.4.1. Market Estimation, 2013 – 2018

9.2.7.5.4.2. Market Forecast, 2019 – 2027

9.2.7.5.5. Latin America

9.2.7.5.5.1. Market Estimation, 2013 – 2018

9.2.7.5.5.2. Market Forecast, 2019 – 2027

9.2.8. Immunology

9.2.8.1. Definition

9.2.8.2. Market Estimation and Penetration, 2013 – 2018

9.2.8.3. Market Forecast, 2019 – 2027

9.2.8.4. Compound Annual Growth Rate (CAGR)

9.2.8.5. Regional Bifurcation

9.2.8.5.1. North America

9.2.8.5.1.1. Market Estimation, 2013 – 2018

9.2.8.5.1.2. Market Forecast, 2019 – 2027

9.2.8.5.2. Europe

9.2.8.5.2.1. Market Estimation, 2013 – 2018

9.2.8.5.2.2. Market Forecast, 2019 – 2027

9.2.8.5.3. Asia Pacific

9.2.8.5.3.1. Market Estimation, 2013 – 2018

9.2.8.5.3.2. Market Forecast, 2019 – 2027

9.2.8.5.4. Middle East and Africa

9.2.8.5.4.1. Market Estimation, 2013 – 2018

9.2.8.5.4.2. Market Forecast, 2019 – 2027

9.2.8.5.5. Latin America

9.2.8.5.5.1. Market Estimation, 2013 – 2018

9.2.8.5.5.2. Market Forecast, 2019 – 2027

9.2.9. Neuroscience

9.2.9.1. Definition

9.2.9.2. Market Estimation and Penetration, 2013 – 2018

9.2.9.3. Market Forecast, 2019 – 2027

9.2.9.4. Compound Annual Growth Rate (CAGR)

9.2.9.5. Regional Bifurcation

9.2.9.5.1. North America

9.2.9.5.1.1. Market Estimation, 2013 – 2018

9.2.9.5.1.2. Market Forecast, 2019 – 2027

9.2.9.5.2. Europe

9.2.9.5.2.1. Market Estimation, 2013 – 2018

9.2.9.5.2.2. Market Forecast, 2019 – 2027

9.2.9.5.3. Asia Pacific

9.2.9.5.3.1. Market Estimation, 2013 – 2018

9.2.9.5.3.2. Market Forecast, 2019 – 2027

9.2.9.5.4. Middle East and Africa

9.2.9.5.4.1. Market Estimation, 2013 – 2018

9.2.9.5.4.2. Market Forecast, 2019 – 2027

9.2.9.5.5. Latin America

9.2.9.5.5.1. Market Estimation, 2013 – 2018

9.2.9.5.5.2. Market Forecast, 2019 – 2027

9.2.10. Respiratory

9.2.10.1. Definition

9.2.10.2. Market Estimation and Penetration, 2013 – 2018

9.2.10.3. Market Forecast, 2019 – 2027

9.2.10.4. Compound Annual Growth Rate (CAGR)

9.2.10.5. Regional Bifurcation

9.2.10.5.1. North America

9.2.10.5.1.1. Market Estimation, 2013 – 2018

9.2.10.5.1.2. Market Forecast, 2019 – 2027

9.2.10.5.2. Europe

9.2.10.5.2.1. Market Estimation, 2013 – 2018

9.2.10.5.2.2. Market Forecast, 2019 – 2027

9.2.10.5.3. Asia Pacific

9.2.10.5.3.1. Market Estimation, 2013 – 2018

9.2.10.5.3.2. Market Forecast, 2019 – 2027

9.2.10.5.4. Middle East and Africa

9.2.10.5.4.1. Market Estimation, 2013 – 2018

9.2.10.5.4.2. Market Forecast, 2019 – 2027

9.2.10.5.5. Latin America

9.2.10.5.5.1. Market Estimation, 2013 – 2018

9.2.10.5.5.2. Market Forecast, 2019 – 2027

9.2.11. Urology

9.2.11.1. Definition

9.2.11.2. Market Estimation and Penetration, 2013 – 2018

9.2.11.3. Market Forecast, 2019 – 2027

9.2.11.4. Compound Annual Growth Rate (CAGR)

9.2.11.5. Regional Bifurcation

9.2.11.5.1. North America

9.2.11.5.1.1. Market Estimation, 2013 – 2018

9.2.11.5.1.2. Market Forecast, 2019 – 2027

9.2.11.5.2. Europe

9.2.11.5.2.1. Market Estimation, 2013 – 2018

9.2.11.5.2.2. Market Forecast, 2019 – 2027

9.2.11.5.3. Asia Pacific

9.2.11.5.3.1. Market Estimation, 2013 – 2018

9.2.11.5.3.2. Market Forecast, 2019 – 2027

9.2.11.5.4. Middle East and Africa

9.2.11.5.4.1. Market Estimation, 2013 – 2018

9.2.11.5.4.2. Market Forecast, 2019 – 2027

9.2.11.5.5. Latin America

9.2.11.5.5.1. Market Estimation, 2013 – 2018

9.2.11.5.5.2. Market Forecast, 2019 – 2027

9.2.12. Others

9.2.12.1. Definition

9.2.12.2. Market Estimation and Penetration, 2013 – 2018

9.2.12.3. Market Forecast, 2019 – 2027

9.2.12.4. Compound Annual Growth Rate (CAGR)

9.2.12.5. Regional Bifurcation

9.2.12.5.1. North America

9.2.12.5.1.1. Market Estimation, 2013 – 2018

9.2.12.5.1.2. Market Forecast, 2019 – 2027

9.2.12.5.2. Europe

9.2.12.5.2.1. Market Estimation, 2013 – 2018

9.2.12.5.2.2. Market Forecast, 2019 – 2027

9.2.12.5.3. Asia Pacific

9.2.12.5.3.1. Market Estimation, 2013 – 2018

9.2.12.5.3.2. Market Forecast, 2019 – 2027

9.2.12.5.4. Middle East and Africa

9.2.12.5.4.1. Market Estimation, 2013 – 2018

9.2.12.5.4.2. Market Forecast, 2019 – 2027

9.2.12.5.5. Latin America

9.2.12.5.5.1. Market Estimation, 2013 – 2018

9.2.12.5.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Application/Therapeutics

10. North America Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 - 2027

10.1. Overview

10.1.1. North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

10.2. North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

10.2.1. Kits and Buffers

10.2.2. Culture Medium

10.2.2.1. Natural Media

10.2.2.1.1. Plasma

10.2.2.1.2. Serum

10.2.2.1.3. Lymph

10.2.2.1.4. Human Placental Cord Serum

10.2.2.1.5. Amniotic Fluid

10.2.2.1.6. Others

10.2.2.2. Artificial Media

10.2.2.2.1. MEM

10.2.2.2.2. RPMI

10.2.2.2.3. PBS

10.2.2.2.4. DPBS

10.2.2.2.5. HBSS

10.2.2.2.6. EBSS

10.2.2.2.7. Others

10.2.3. Cryopreservation Media

10.2.4. Diagnostic Assay

10.2.5. Others

10.3. North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

10.3.1. Cardiovascular

10.3.2. Dermatology

10.3.3. Endocrine and Metabolic

10.3.4. Gastroenterology

10.3.5. Hematology and Oncology

10.3.6. Obstetrics

10.3.7. Critical Care

10.3.8. Immunology

10.3.9. Neuroscience

10.3.10. Respiratory

10.3.11. Urology

10.3.12. Others

10.4. North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1. U.S Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.1.1.1. Kits and Buffers

10.4.1.1.2. Culture Medium

10.4.1.1.2.1. Natural Media

10.4.1.1.2.1.1. Plasma

10.4.1.1.2.1.2. Serum

10.4.1.1.2.1.3. Lymph

10.4.1.1.2.1.4. Human Placental Cord Serum

10.4.1.1.2.1.5. Amniotic Fluid

10.4.1.1.2.1.6. Others

10.4.1.1.2.2. Artificial Media

10.4.1.1.2.2.1. MEM

10.4.1.1.2.2.2. RPMI

10.4.1.1.2.2.3. PBS

10.4.1.1.2.2.4. DPBS

10.4.1.1.2.2.5. HBSS

10.4.1.1.2.2.6. EBSS

10.4.1.1.2.2.7. Others

10.4.1.1.3. Cryopreservation Media

10.4.1.1.4. Diagnostic Assay

10.4.1.1.5. Others

10.4.1.2. U.S Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

10.4.1.2.1. Cardiovascular

10.4.1.2.2. Dermatology

10.4.1.2.3. Endocrine and Metabolic

10.4.1.2.4. Gastroenterology

10.4.1.2.5. Hematology and Oncology

10.4.1.2.6. Obstetrics

10.4.1.2.7. Critical Care

10.4.1.2.8. Immunology

10.4.1.2.9. Neuroscience

10.4.1.2.10. Respiratory

10.4.1.2.11. Urology

10.4.1.2.12. Others

10.4.2. Canada

10.4.2.1. Canada Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.2.1.1. Kits and Buffers

10.4.2.1.2. Culture Medium

10.4.2.1.2.1. Natural Media

10.4.2.1.2.1.1. Plasma

10.4.2.1.2.1.2. Serum

10.4.2.1.2.1.3. Lymph

10.4.2.1.2.1.4. Human Placental Cord Serum

10.4.2.1.2.1.5. Amniotic Fluid

10.4.2.1.2.1.6. Others

10.4.2.1.2.2. Artificial Media

10.4.2.1.2.2.1. MEM

10.4.2.1.2.2.2. RPMI

10.4.2.1.2.2.3. PBS

10.4.2.1.2.2.4. DPBS

10.4.2.1.2.2.5. HBSS

10.4.2.1.2.2.6. EBSS

10.4.2.1.2.2.7. Others

10.4.2.1.3. Cryopreservation Media

10.4.2.1.4. Diagnostic Assay

10.4.2.1.5. Others

10.4.2.2. Canada Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

10.4.2.2.1. Cardiovascular

10.4.2.2.2. Dermatology

10.4.2.2.3. Endocrine and Metabolic

10.4.2.2.4. Gastroenterology

10.4.2.2.5. Hematology and Oncology

10.4.2.2.6. Obstetrics

10.4.2.2.7. Critical Care

10.4.2.2.8. Immunology

10.4.2.2.9. Neuroscience

10.4.2.2.10. Respiratory

10.4.2.2.11. Urology

10.4.2.2.12. Others

10.4.3. Mexico

10.4.3.1. Mexico Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.3.1.1. Kits and Buffers

10.4.3.1.2. Culture Medium

10.4.3.1.2.1. Natural Media

10.4.3.1.2.1.1. Plasma

10.4.3.1.2.1.2. Serum

10.4.3.1.2.1.3. Lymph

10.4.3.1.2.1.4. Human Placental Cord Serum

10.4.3.1.2.1.5. Amniotic Fluid

10.4.3.1.2.1.6. Others

10.4.3.1.2.2. Artificial Media

10.4.3.1.2.2.1. MEM

10.4.3.1.2.2.2. RPMI

10.4.3.1.2.2.3. PBS

10.4.3.1.2.2.4. DPBS

10.4.3.1.2.2.5. HBSS

10.4.3.1.2.2.6. EBSS

10.4.3.1.2.2.7. Others

10.4.3.1.3. Cryopreservation Media

10.4.3.1.4. Diagnostic Assay

10.4.3.1.5. Others

10.4.3.2. Mexico Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

10.4.3.2.1. Cardiovascular

10.4.3.2.2. Dermatology

10.4.3.2.3. Endocrine and Metabolic

10.4.3.2.4. Gastroenterology

10.4.3.2.5. Hematology and Oncology

10.4.3.2.6. Obstetrics

10.4.3.2.7. Critical Care

10.4.3.2.8. Immunology

10.4.3.2.9. Neuroscience

10.4.3.2.10. Respiratory

10.4.3.2.11. Urology

10.4.3.2.12. Others

10.4.4. Rest of North America

10.4.4.1. Rest of North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.4.1.1. Kits and Buffers

10.4.4.1.2. Culture Medium

10.4.4.1.2.1. Natural Media

10.4.4.1.2.1.1. Plasma

10.4.4.1.2.1.2. Serum

10.4.4.1.2.1.3. Lymph

10.4.4.1.2.1.4. Human Placental Cord Serum

10.4.4.1.2.1.5. Amniotic Fluid

10.4.4.1.2.1.6. Others

10.4.4.1.2.2. Artificial Media

10.4.4.1.2.2.1. MEM

10.4.4.1.2.2.2. RPMI

10.4.4.1.2.2.3. PBS

10.4.4.1.2.2.4. DPBS

10.4.4.1.2.2.5. HBSS

10.4.4.1.2.2.6. EBSS

10.4.4.1.2.2.7. Others

10.4.4.1.3. Cryopreservation Media

10.4.4.1.4. Diagnostic Assay

10.4.4.1.5. Others

10.4.4.2. Rest of North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

10.4.4.2.1. Cardiovascular

10.4.4.2.2. Dermatology

10.4.4.2.3. Endocrine and Metabolic

10.4.4.2.4. Gastroenterology

10.4.4.2.5. Hematology and Oncology

10.4.4.2.6. Obstetrics

10.4.4.2.7. Critical Care

10.4.4.2.8. Immunology

10.4.4.2.9. Neuroscience

10.4.4.2.10. Respiratory

10.4.4.2.11. Urology

10.4.4.2.12. Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product Type

10.5.3. By Application/Therapeutics

11. Europe Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 - 2027

11.1. Overview

11.1.1. Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

11.2. Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.2.1. Kits and Buffers

11.2.2. Culture Medium

11.2.2.1. Natural Media

11.2.2.1.1. Plasma

11.2.2.1.2. Serum

11.2.2.1.3. Lymph

11.2.2.1.4. Human Placental Cord Serum

11.2.2.1.5. Amniotic Fluid

11.2.2.1.6. Others

11.2.2.2. Artificial Media

11.2.2.2.1. MEM

11.2.2.2.2. RPMI

11.2.2.2.3. PBS

11.2.2.2.4. DPBS

11.2.2.2.5. HBSS

11.2.2.2.6. EBSS

11.2.2.2.7. Others

11.2.3. Cryopreservation Media

11.2.4. Diagnostic Assay

11.2.5. Others

11.3. Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.3.1. Cardiovascular

11.3.2. Dermatology

11.3.3. Endocrine and Metabolic

11.3.4. Gastroenterology

11.3.5. Hematology and Oncology

11.3.6. Obstetrics

11.3.7. Critical Care

11.3.8. Immunology

11.3.9. Neuroscience

11.3.10. Respiratory

11.3.11. Urology

11.3.12. Others

11.4. Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1. France Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.1.1.1. Kits and Buffers

11.4.1.1.2. Culture Medium

11.4.1.1.2.1. Natural Media

11.4.1.1.2.1.1. Plasma

11.4.1.1.2.1.2. Serum

11.4.1.1.2.1.3. Lymph

11.4.1.1.2.1.4. Human Placental Cord Serum

11.4.1.1.2.1.5. Amniotic Fluid

11.4.1.1.2.1.6. Others

11.4.1.1.2.2. Artificial Media

11.4.1.1.2.2.1. MEM

11.4.1.1.2.2.2. RPMI

11.4.1.1.2.2.3. PBS

11.4.1.1.2.2.4. DPBS

11.4.1.1.2.2.5. HBSS

11.4.1.1.2.2.6. EBSS

11.4.1.1.2.2.7. Others

11.4.1.1.3. Cryopreservation Media

11.4.1.1.4. Diagnostic Assay

11.4.1.1.5. Others

11.4.1.2. France Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.1.2.1. Cardiovascular

11.4.1.2.2. Dermatology

11.4.1.2.3. Endocrine and Metabolic

11.4.1.2.4. Gastroenterology

11.4.1.2.5. Hematology and Oncology

11.4.1.2.6. Obstetrics

11.4.1.2.7. Critical Care

11.4.1.2.8. Immunology

11.4.1.2.9. Neuroscience

11.4.1.2.10. Respiratory

11.4.1.2.11. Urology

11.4.1.2.12. Others

11.4.2. The UK

11.4.2.1. The UK Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.2.1.1. Kits and Buffers

11.4.2.1.2. Culture Medium

11.4.2.1.2.1. Natural Media

11.4.2.1.2.1.1. Plasma

11.4.2.1.2.1.2. Serum

11.4.2.1.2.1.3. Lymph

11.4.2.1.2.1.4. Human Placental Cord Serum

11.4.2.1.2.1.5. Amniotic Fluid

11.4.2.1.2.1.6. Others

11.4.2.1.2.2. Artificial Media

11.4.2.1.2.2.1. MEM

11.4.2.1.2.2.2. RPMI

11.4.2.1.2.2.3. PBS

11.4.2.1.2.2.4. DPBS

11.4.2.1.2.2.5. HBSS

11.4.2.1.2.2.6. EBSS

11.4.2.1.2.2.7. Others

11.4.2.1.3. Cryopreservation Media

11.4.2.1.4. Diagnostic Assay

11.4.2.1.5. Others

11.4.2.2. The UK Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.2.2.1. Cardiovascular

11.4.2.2.2. Dermatology

11.4.2.2.3. Endocrine and Metabolic

11.4.2.2.4. Gastroenterology

11.4.2.2.5. Hematology and Oncology

11.4.2.2.6. Obstetrics

11.4.2.2.7. Critical Care

11.4.2.2.8. Immunology

11.4.2.2.9. Neuroscience

11.4.2.2.10. Respiratory

11.4.2.2.11. Urology

11.4.2.2.12. Others

11.4.3. Spain

11.4.3.1. Spain Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.3.1.1. Kits and Buffers

11.4.3.1.2. Culture Medium

11.4.3.1.2.1. Natural Media

11.4.3.1.2.1.1. Plasma

11.4.3.1.2.1.2. Serum

11.4.3.1.2.1.3. Lymph

11.4.3.1.2.1.4. Human Placental Cord Serum

11.4.3.1.2.1.5. Amniotic Fluid

11.4.3.1.2.1.6. Others

11.4.3.1.2.2. Artificial Media

11.4.3.1.2.2.1. MEM

11.4.3.1.2.2.2. RPMI

11.4.3.1.2.2.3. PBS

11.4.3.1.2.2.4. DPBS

11.4.3.1.2.2.5. HBSS

11.4.3.1.2.2.6. EBSS

11.4.3.1.2.2.7. Others

11.4.3.1.3. Cryopreservation Media

11.4.3.1.4. Diagnostic Assay

11.4.3.1.5. Others

11.4.3.2. Spain Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.3.2.1. Cardiovascular

11.4.3.2.2. Dermatology

11.4.3.2.3. Endocrine and Metabolic

11.4.3.2.4. Gastroenterology

11.4.3.2.5. Hematology and Oncology

11.4.3.2.6. Obstetrics

11.4.3.2.7. Critical Care

11.4.3.2.8. Immunology

11.4.3.2.9. Neuroscience

11.4.3.2.10. Respiratory

11.4.3.2.11. Urology

11.4.3.2.12. Others

11.4.4. Germany

11.4.4.1. Germany Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.4.1.1. Kits and Buffers

11.4.4.1.2. Culture Medium

11.4.4.1.2.1. Natural Media

11.4.4.1.2.1.1. Plasma

11.4.4.1.2.1.2. Serum

11.4.4.1.2.1.3. Lymph

11.4.4.1.2.1.4. Human Placental Cord Serum

11.4.4.1.2.1.5. Amniotic Fluid

11.4.4.1.2.1.6. Others

11.4.4.1.2.2. Artificial Media

11.4.4.1.2.2.1. MEM

11.4.4.1.2.2.2. RPMI

11.4.4.1.2.2.3. PBS

11.4.4.1.2.2.4. DPBS

11.4.4.1.2.2.5. HBSS

11.4.4.1.2.2.6. EBSS

11.4.4.1.2.2.7. Others

11.4.4.1.3. Cryopreservation Media

11.4.4.1.4. Diagnostic Assay

11.4.4.1.5. Others

11.4.4.2. Germany Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.4.2.1. Cardiovascular

11.4.4.2.2. Dermatology

11.4.4.2.3. Endocrine and Metabolic

11.4.4.2.4. Gastroenterology

11.4.4.2.5. Hematology and Oncology

11.4.4.2.6. Obstetrics

11.4.4.2.7. Critical Care

11.4.4.2.8. Immunology

11.4.4.2.9. Neuroscience

11.4.4.2.10. Respiratory

11.4.4.2.11. Urology

11.4.4.2.12. Others

11.4.5. Italy

11.4.5.1. Italy Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.5.1.1. Kits and Buffers

11.4.5.1.2. Culture Medium

11.4.5.1.2.1. Natural Media

11.4.5.1.2.1.1. Plasma

11.4.5.1.2.1.2. Serum

11.4.5.1.2.1.3. Lymph

11.4.5.1.2.1.4. Human Placental Cord Serum

11.4.5.1.2.1.5. Amniotic Fluid

11.4.5.1.2.1.6. Others

11.4.5.1.2.2. Artificial Media

11.4.5.1.2.2.1. MEM

11.4.5.1.2.2.2. RPMI

11.4.5.1.2.2.3. PBS

11.4.5.1.2.2.4. DPBS

11.4.5.1.2.2.5. HBSS

11.4.5.1.2.2.6. EBSS

11.4.5.1.2.2.7. Others

11.4.5.1.3. Cryopreservation Media

11.4.5.1.4. Diagnostic Assay

11.4.5.1.5. Others

11.4.5.2. Italy Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.5.2.1. Cardiovascular

11.4.5.2.2. Dermatology

11.4.5.2.3. Endocrine and Metabolic

11.4.5.2.4. Gastroenterology

11.4.5.2.5. Hematology and Oncology

11.4.5.2.6. Obstetrics

11.4.5.2.7. Critical Care

11.4.5.2.8. Immunology

11.4.5.2.9. Neuroscience

11.4.5.2.10. Respiratory

11.4.5.2.11. Urology

11.4.5.2.12. Others

11.4.6. Nordic Countries

11.4.6.1. Nordic Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.6.1.1. Kits and Buffers

11.4.6.1.2. Culture Medium

11.4.6.1.2.1. Natural Media

11.4.6.1.2.1.1. Plasma

11.4.6.1.2.1.2. Serum

11.4.6.1.2.1.3. Lymph

11.4.6.1.2.1.4. Human Placental Cord Serum

11.4.6.1.2.1.5. Amniotic Fluid

11.4.6.1.2.1.6. Others

11.4.6.1.2.2. Artificial Media

11.4.6.1.2.2.1. MEM

11.4.6.1.2.2.2. RPMI

11.4.6.1.2.2.3. PBS

11.4.6.1.2.2.4. DPBS

11.4.6.1.2.2.5. HBSS

11.4.6.1.2.2.6. EBSS

11.4.6.1.2.2.7. Others

11.4.6.1.3. Cryopreservation Media

11.4.6.1.4. Diagnostic Assay

11.4.6.1.5. Others

11.4.6.2. Nordic Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.6.2.1. Cardiovascular

11.4.6.2.2. Dermatology

11.4.6.2.3. Endocrine and Metabolic

11.4.6.2.4. Gastroenterology

11.4.6.2.5. Hematology and Oncology

11.4.6.2.6. Obstetrics

11.4.6.2.7. Critical Care

11.4.6.2.8. Immunology

11.4.6.2.9. Neuroscience

11.4.6.2.10. Respiratory

11.4.6.2.11. Urology

11.4.6.2.12. Others

11.4.6.3. Nordic Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1. Denmark

11.4.6.3.2. Finland

11.4.6.3.3. Iceland

11.4.6.3.4. Sweden

11.4.6.3.5. Norway

11.4.7. Benelux Union

11.4.7.1. Benelux Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.7.1.1. Kits and Buffers

11.4.7.1.2. Culture Medium

11.4.7.1.2.1. Natural Media

11.4.7.1.2.1.1. Plasma

11.4.7.1.2.1.2. Serum

11.4.7.1.2.1.3. Lymph

11.4.7.1.2.1.4. Human Placental Cord Serum

11.4.7.1.2.1.5. Amniotic Fluid

11.4.7.1.2.1.6. Others

11.4.7.1.2.2. Artificial Media

11.4.7.1.2.2.1. MEM

11.4.7.1.2.2.2. RPMI

11.4.7.1.2.2.3. PBS

11.4.7.1.2.2.4. DPBS

11.4.7.1.2.2.5. HBSS

11.4.7.1.2.2.6. EBSS

11.4.7.1.2.2.7. Others

11.4.7.1.3. Cryopreservation Media

11.4.7.1.4. Diagnostic Assay

11.4.7.1.5. Others

11.4.7.2. Benelux Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.7.2.1. Cardiovascular

11.4.7.2.2. Dermatology

11.4.7.2.3. Endocrine and Metabolic

11.4.7.2.4. Gastroenterology

11.4.7.2.5. Hematology and Oncology

11.4.7.2.6. Obstetrics

11.4.7.2.7. Critical Care

11.4.7.2.8. Immunology

11.4.7.2.9. Neuroscience

11.4.7.2.10. Respiratory

11.4.7.2.11. Urology

11.4.7.2.12. Others

11.4.7.3. Benelux Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1. Belgium

11.4.7.3.2. The Netherlands

11.4.7.3.3. Luxembourg

11.4.8. Rest of Europe

11.4.8.1. Rest of Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.8.1.1. Kits and Buffers

11.4.8.1.2. Culture Medium

11.4.8.1.2.1. Natural Media

11.4.8.1.2.1.1. Plasma

11.4.8.1.2.1.2. Serum

11.4.8.1.2.1.3. Lymph

11.4.8.1.2.1.4. Human Placental Cord Serum

11.4.8.1.2.1.5. Amniotic Fluid

11.4.8.1.2.1.6. Others

11.4.8.1.2.2. Artificial Media

11.4.8.1.2.2.1. MEM

11.4.8.1.2.2.2. RPMI

11.4.8.1.2.2.3. PBS

11.4.8.1.2.2.4. DPBS

11.4.8.1.2.2.5. HBSS

11.4.8.1.2.2.6. EBSS

11.4.8.1.2.2.7. Others

11.4.8.1.3. Cryopreservation Media

11.4.8.1.4. Diagnostic Assay

11.4.8.1.5. Others

11.4.8.2. Rest of Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

11.4.8.2.1. Cardiovascular

11.4.8.2.2. Dermatology

11.4.8.2.3. Endocrine and Metabolic

11.4.8.2.4. Gastroenterology

11.4.8.2.5. Hematology and Oncology

11.4.8.2.6. Obstetrics

11.4.8.2.7. Critical Care

11.4.8.2.8. Immunology

11.4.8.2.9. Neuroscience

11.4.8.2.10. Respiratory

11.4.8.2.11. Urology

11.4.8.2.12. Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product Type

11.5.3. By Application/Therapeutics

12. Asia Pacific Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

12.2. Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.2.1. Kits and Buffers

12.2.2. Culture Medium

12.2.2.1. Natural Media

12.2.2.1.1. Plasma

12.2.2.1.2. Serum

12.2.2.1.3. Lymph

12.2.2.1.4. Human Placental Cord Serum

12.2.2.1.5. Amniotic Fluid

12.2.2.1.6. Others

12.2.2.2. Artificial Media

12.2.2.2.1. MEM

12.2.2.2.2. RPMI

12.2.2.2.3. PBS

12.2.2.2.4. DPBS

12.2.2.2.5. HBSS

12.2.2.2.6. EBSS

12.2.2.2.7. Others

12.2.3. Cryopreservation Media

12.2.4. Diagnostic Assay

12.2.5. Others

12.3. Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.3.1. Cardiovascular

12.3.2. Dermatology

12.3.3. Endocrine and Metabolic

12.3.4. Gastroenterology

12.3.5. Hematology and Oncology

12.3.6. Obstetrics

12.3.7. Critical Care

12.3.8. Immunology

12.3.9. Neuroscience

12.3.10. Respiratory

12.3.11. Urology

12.3.12. Others

12.4. Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1. China Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.1.1.1. Kits and Buffers

12.4.1.1.2. Culture Medium

12.4.1.1.2.1. Natural Media

12.4.1.1.2.1.1. Plasma

12.4.1.1.2.1.2. Serum

12.4.1.1.2.1.3. Lymph

12.4.1.1.2.1.4. Human Placental Cord Serum

12.4.1.1.2.1.5. Amniotic Fluid

12.4.1.1.2.1.6. Others

12.4.1.1.2.2. Artificial Media

12.4.1.1.2.2.1. MEM

12.4.1.1.2.2.2. RPMI

12.4.1.1.2.2.3. PBS

12.4.1.1.2.2.4. DPBS

12.4.1.1.2.2.5. HBSS

12.4.1.1.2.2.6. EBSS

12.4.1.1.2.2.7. Others

12.4.1.1.3. Cryopreservation Media

12.4.1.1.4. Diagnostic Assay

12.4.1.1.5. Others

12.4.1.2. China Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.1.2.1. Cardiovascular

12.4.1.2.2. Dermatology

12.4.1.2.3. Endocrine and Metabolic

12.4.1.2.4. Gastroenterology

12.4.1.2.5. Hematology and Oncology

12.4.1.2.6. Obstetrics

12.4.1.2.7. Critical Care

12.4.1.2.8. Immunology

12.4.1.2.9. Neuroscience

12.4.1.2.10. Respiratory

12.4.1.2.11. Urology

12.4.1.2.12. Others

12.4.2. Japan

12.4.2.1. Japan Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.2.1.1. Kits and Buffers

12.4.2.1.2. Culture Medium

12.4.2.1.2.1. Natural Media

12.4.2.1.2.1.1. Plasma

12.4.2.1.2.1.2. Serum

12.4.2.1.2.1.3. Lymph

12.4.2.1.2.1.4. Human Placental Cord Serum

12.4.2.1.2.1.5. Amniotic Fluid

12.4.2.1.2.1.6. Others

12.4.2.1.2.2. Artificial Media

12.4.2.1.2.2.1. MEM

12.4.2.1.2.2.2. RPMI

12.4.2.1.2.2.3. PBS

12.4.2.1.2.2.4. DPBS

12.4.2.1.2.2.5. HBSS

12.4.2.1.2.2.6. EBSS

12.4.2.1.2.2.7. Others

12.4.2.1.3. Cryopreservation Media

12.4.2.1.4. Diagnostic Assay

12.4.2.1.5. Others

12.4.2.2. Japan Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.2.2.1. Cardiovascular

12.4.2.2.2. Dermatology

12.4.2.2.3. Endocrine and Metabolic

12.4.2.2.4. Gastroenterology

12.4.2.2.5. Hematology and Oncology

12.4.2.2.6. Obstetrics

12.4.2.2.7. Critical Care

12.4.2.2.8. Immunology

12.4.2.2.9. Neuroscience

12.4.2.2.10. Respiratory

12.4.2.2.11. Urology

12.4.2.2.12. Others

12.4.3. India

12.4.3.1. India Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.3.1.1. Kits and Buffers

12.4.3.1.2. Culture Medium

12.4.3.1.2.1. Natural Media

12.4.3.1.2.1.1. Plasma

12.4.3.1.2.1.2. Serum

12.4.3.1.2.1.3. Lymph

12.4.3.1.2.1.4. Human Placental Cord Serum

12.4.3.1.2.1.5. Amniotic Fluid

12.4.3.1.2.1.6. Others

12.4.3.1.2.2. Artificial Media

12.4.3.1.2.2.1. MEM

12.4.3.1.2.2.2. RPMI

12.4.3.1.2.2.3. PBS

12.4.3.1.2.2.4. DPBS

12.4.3.1.2.2.5. HBSS

12.4.3.1.2.2.6. EBSS

12.4.3.1.2.2.7. Others

12.4.3.1.3. Cryopreservation Media

12.4.3.1.4. Diagnostic Assay

12.4.3.1.5. Others

12.4.3.2. India Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.3.2.1. Cardiovascular

12.4.3.2.2. Dermatology

12.4.3.2.3. Endocrine and Metabolic

12.4.3.2.4. Gastroenterology

12.4.3.2.5. Hematology and Oncology

12.4.3.2.6. Obstetrics

12.4.3.2.7. Critical Care

12.4.3.2.8. Immunology

12.4.3.2.9. Neuroscience

12.4.3.2.10. Respiratory

12.4.3.2.11. Urology

12.4.3.2.12. Others

12.4.4. New Zealand

12.4.4.1. New Zealand Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.4.1.1. Kits and Buffers

12.4.4.1.2. Culture Medium

12.4.4.1.2.1. Natural Media

12.4.4.1.2.1.1. Plasma

12.4.4.1.2.1.2. Serum

12.4.4.1.2.1.3. Lymph

12.4.4.1.2.1.4. Human Placental Cord Serum

12.4.4.1.2.1.5. Amniotic Fluid

12.4.4.1.2.1.6. Others

12.4.4.1.2.2. Artificial Media

12.4.4.1.2.2.1. MEM

12.4.4.1.2.2.2. RPMI

12.4.4.1.2.2.3. PBS

12.4.4.1.2.2.4. DPBS

12.4.4.1.2.2.5. HBSS

12.4.4.1.2.2.6. EBSS

12.4.4.1.2.2.7. Others

12.4.4.1.3. Cryopreservation Media

12.4.4.1.4. Diagnostic Assay

12.4.4.1.5. Others

12.4.4.2. New Zealand Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.4.2.1. Cardiovascular

12.4.4.2.2. Dermatology

12.4.4.2.3. Endocrine and Metabolic

12.4.4.2.4. Gastroenterology

12.4.4.2.5. Hematology and Oncology

12.4.4.2.6. Obstetrics

12.4.4.2.7. Critical Care

12.4.4.2.8. Immunology

12.4.4.2.9. Neuroscience

12.4.4.2.10. Respiratory

12.4.4.2.11. Urology

12.4.4.2.12. Others

12.4.5. Australia

12.4.5.1. Australia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.5.1.1. Kits and Buffers

12.4.5.1.2. Culture Medium

12.4.5.1.2.1. Natural Media

12.4.5.1.2.1.1. Plasma

12.4.5.1.2.1.2. Serum

12.4.5.1.2.1.3. Lymph

12.4.5.1.2.1.4. Human Placental Cord Serum

12.4.5.1.2.1.5. Amniotic Fluid

12.4.5.1.2.1.6. Others

12.4.5.1.2.2. Artificial Media

12.4.5.1.2.2.1. MEM

12.4.5.1.2.2.2. RPMI

12.4.5.1.2.2.3. PBS

12.4.5.1.2.2.4. DPBS

12.4.5.1.2.2.5. HBSS

12.4.5.1.2.2.6. EBSS

12.4.5.1.2.2.7. Others

12.4.5.1.3. Cryopreservation Media

12.4.5.1.4. Diagnostic Assay

12.4.5.1.5. Others

12.4.5.2. Australia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.5.2.1. Cardiovascular

12.4.5.2.2. Dermatology

12.4.5.2.3. Endocrine and Metabolic

12.4.5.2.4. Gastroenterology

12.4.5.2.5. Hematology and Oncology

12.4.5.2.6. Obstetrics

12.4.5.2.7. Critical Care

12.4.5.2.8. Immunology

12.4.5.2.9. Neuroscience

12.4.5.2.10. Respiratory

12.4.5.2.11. Urology

12.4.5.2.12. Others

12.4.6. South Korea

12.4.6.1. South Korea Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.6.1.1. Kits and Buffers

12.4.6.1.2. Culture Medium

12.4.6.1.2.1. Natural Media

12.4.6.1.2.1.1. Plasma

12.4.6.1.2.1.2. Serum

12.4.6.1.2.1.3. Lymph

12.4.6.1.2.1.4. Human Placental Cord Serum

12.4.6.1.2.1.5. Amniotic Fluid

12.4.6.1.2.1.6. Others

12.4.6.1.2.2. Artificial Media

12.4.6.1.2.2.1. MEM

12.4.6.1.2.2.2. RPMI

12.4.6.1.2.2.3. PBS

12.4.6.1.2.2.4. DPBS

12.4.6.1.2.2.5. HBSS

12.4.6.1.2.2.6. EBSS

12.4.6.1.2.2.7. Others

12.4.6.1.3. Cryopreservation Media

12.4.6.1.4. Diagnostic Assay

12.4.6.1.5. Others

12.4.6.2. South Korea Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.6.2.1. Cardiovascular

12.4.6.2.2. Dermatology

12.4.6.2.3. Endocrine and Metabolic

12.4.6.2.4. Gastroenterology

12.4.6.2.5. Hematology and Oncology

12.4.6.2.6. Obstetrics

12.4.6.2.7. Critical Care

12.4.6.2.8. Immunology

12.4.6.2.9. Neuroscience

12.4.6.2.10. Respiratory

12.4.6.2.11. Urology

12.4.6.2.12. Others

12.4.7. Southeast Asia

12.4.7.1. Southeast Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.7.1.1. Kits and Buffers

12.4.7.1.2. Culture Medium

12.4.7.1.2.1. Natural Media

12.4.7.1.2.1.1. Plasma

12.4.7.1.2.1.2. Serum

12.4.7.1.2.1.3. Lymph

12.4.7.1.2.1.4. Human Placental Cord Serum

12.4.7.1.2.1.5. Amniotic Fluid

12.4.7.1.2.1.6. Others

12.4.7.1.2.2. Artificial Media

12.4.7.1.2.2.1. MEM

12.4.7.1.2.2.2. RPMI

12.4.7.1.2.2.3. PBS

12.4.7.1.2.2.4. DPBS

12.4.7.1.2.2.5. HBSS

12.4.7.1.2.2.6. EBSS

12.4.7.1.2.2.7. Others

12.4.7.1.3. Cryopreservation Media

12.4.7.1.4. Diagnostic Assay

12.4.7.1.5. Others

12.4.7.2. Southeast Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.7.2.1. Cardiovascular

12.4.7.2.2. Dermatology

12.4.7.2.3. Endocrine and Metabolic

12.4.7.2.4. Gastroenterology

12.4.7.2.5. Hematology and Oncology

12.4.7.2.6. Obstetrics

12.4.7.2.7. Critical Care

12.4.7.2.8. Immunology

12.4.7.2.9. Neuroscience

12.4.7.2.10. Respiratory

12.4.7.2.11. Urology

12.4.7.2.12. Others

12.4.7.3. Southeast Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1. Indonesia

12.4.7.3.2. Thailand

12.4.7.3.3. Malaysia

12.4.7.3.4. Singapore

12.4.7.3.5. Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1. Rest of Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

12.4.8.1.1. Kits and Buffers

12.4.8.1.2. Culture Medium

12.4.8.1.2.1. Natural Media

12.4.8.1.2.1.1. Plasma

12.4.8.1.2.1.2. Serum

12.4.8.1.2.1.3. Lymph

12.4.8.1.2.1.4. Human Placental Cord Serum

12.4.8.1.2.1.5. Amniotic Fluid

12.4.8.1.2.1.6. Others

12.4.8.1.2.2. Artificial Media

12.4.8.1.2.2.1. MEM

12.4.8.1.2.2.2. RPMI

12.4.8.1.2.2.3. PBS

12.4.8.1.2.2.4. DPBS

12.4.8.1.2.2.5. HBSS

12.4.8.1.2.2.6. EBSS

12.4.8.1.2.2.7. Others

12.4.8.1.3. Cryopreservation Media

12.4.8.1.4. Diagnostic Assay

12.4.8.1.5. Others

12.4.8.2. Rest of Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

12.4.8.2.1. Cardiovascular

12.4.8.2.2. Dermatology

12.4.8.2.3. Endocrine and Metabolic

12.4.8.2.4. Gastroenterology

12.4.8.2.5. Hematology and Oncology

12.4.8.2.6. Obstetrics

12.4.8.2.7. Critical Care

12.4.8.2.8. Immunology

12.4.8.2.9. Neuroscience

12.4.8.2.10. Respiratory

12.4.8.2.11. Urology

12.4.8.2.12. Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Product Type

12.5.3. By Application/Therapeutics

13. Middle East and Africa Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Middle East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

13.2. Middle East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.2.1. Kits and Buffers

13.2.2. Culture Medium

13.2.2.1. Natural Media

13.2.2.1.1. Plasma

13.2.2.1.2. Serum

13.2.2.1.3. Lymph

13.2.2.1.4. Human Placental Cord Serum

13.2.2.1.5. Amniotic Fluid

13.2.2.1.6. Others

13.2.2.2. Artificial Media

13.2.2.2.1. MEM

13.2.2.2.2. RPMI

13.2.2.2.3. PBS

13.2.2.2.4. DPBS

13.2.2.2.5. HBSS

13.2.2.2.6. EBSS

13.2.2.2.7. Others

13.2.3. Cryopreservation Media

13.2.4. Diagnostic Assay

13.2.5. Others

13.3. Middle East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.3.1. Cardiovascular

13.3.2. Dermatology

13.3.3. Endocrine and Metabolic

13.3.4. Gastroenterology

13.3.5. Hematology and Oncology

13.3.6. Obstetrics

13.3.7. Critical Care

13.3.8. Immunology

13.3.9. Neuroscience

13.3.10. Respiratory

13.3.11. Urology

13.3.12. Others

13.4. Middle East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1. Saudi Arabia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.1.1.1. Kits and Buffers

13.4.1.1.2. Culture Medium

13.4.1.1.2.1. Natural Media

13.4.1.1.2.1.1. Plasma

13.4.1.1.2.1.2. Serum

13.4.1.1.2.1.3. Lymph

13.4.1.1.2.1.4. Human Placental Cord Serum

13.4.1.1.2.1.5. Amniotic Fluid

13.4.1.1.2.1.6. Others

13.4.1.1.2.2. Artificial Media

13.4.1.1.2.2.1. MEM

13.4.1.1.2.2.2. RPMI

13.4.1.1.2.2.3. PBS

13.4.1.1.2.2.4. DPBS

13.4.1.1.2.2.5. HBSS

13.4.1.1.2.2.6. EBSS

13.4.1.1.2.2.7. Others

13.4.1.1.3. Cryopreservation Media

13.4.1.1.4. Diagnostic Assay

13.4.1.1.5. Others

13.4.1.2. Saudi Arabia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.1.2.1. Cardiovascular

13.4.1.2.2. Dermatology

13.4.1.2.3. Endocrine and Metabolic

13.4.1.2.4. Gastroenterology

13.4.1.2.5. Hematology and Oncology

13.4.1.2.6. Obstetrics

13.4.1.2.7. Critical Care

13.4.1.2.8. Immunology

13.4.1.2.9. Neuroscience

13.4.1.2.10. Respiratory

13.4.1.2.11. Urology

13.4.1.2.12. Others

13.4.2. UAE

13.4.2.1. UAE Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.2.1.1. Kits and Buffers

13.4.2.1.2. Culture Medium

13.4.2.1.2.1. Natural Media

13.4.2.1.2.1.1. Plasma

13.4.2.1.2.1.2. Serum

13.4.2.1.2.1.3. Lymph

13.4.2.1.2.1.4. Human Placental Cord Serum

13.4.2.1.2.1.5. Amniotic Fluid

13.4.2.1.2.1.6. Others

13.4.2.1.2.2. Artificial Media

13.4.2.1.2.2.1. MEM

13.4.2.1.2.2.2. RPMI

13.4.2.1.2.2.3. PBS

13.4.2.1.2.2.4. DPBS

13.4.2.1.2.2.5. HBSS

13.4.2.1.2.2.6. EBSS

13.4.2.1.2.2.7. Others

13.4.2.1.3. Cryopreservation Media

13.4.2.1.4. Diagnostic Assay

13.4.2.1.5. Others

13.4.2.2. UAE Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.2.2.1. Cardiovascular

13.4.2.2.2. Dermatology

13.4.2.2.3. Endocrine and Metabolic

13.4.2.2.4. Gastroenterology

13.4.2.2.5. Hematology and Oncology

13.4.2.2.6. Obstetrics

13.4.2.2.7. Critical Care

13.4.2.2.8. Immunology

13.4.2.2.9. Neuroscience

13.4.2.2.10. Respiratory

13.4.2.2.11. Urology

13.4.2.2.12. Others

13.4.3. Egypt

13.4.3.1. Egypt Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.3.1.1. Kits and Buffers

13.4.3.1.2. Culture Medium

13.4.3.1.2.1. Natural Media

13.4.3.1.2.1.1. Plasma

13.4.3.1.2.1.2. Serum

13.4.3.1.2.1.3. Lymph

13.4.3.1.2.1.4. Human Placental Cord Serum

13.4.3.1.2.1.5. Amniotic Fluid

13.4.3.1.2.1.6. Others

13.4.3.1.2.2. Artificial Media

13.4.3.1.2.2.1. MEM

13.4.3.1.2.2.2. RPMI

13.4.3.1.2.2.3. PBS

13.4.3.1.2.2.4. DPBS

13.4.3.1.2.2.5. HBSS

13.4.3.1.2.2.6. EBSS

13.4.3.1.2.2.7. Others

13.4.3.1.3. Cryopreservation Media

13.4.3.1.4. Diagnostic Assay

13.4.3.1.5. Others

13.4.3.2. Egypt Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.3.2.1. Cardiovascular

13.4.3.2.2. Dermatology

13.4.3.2.3. Endocrine and Metabolic

13.4.3.2.4. Gastroenterology

13.4.3.2.5. Hematology and Oncology

13.4.3.2.6. Obstetrics

13.4.3.2.7. Critical Care

13.4.3.2.8. Immunology

13.4.3.2.9. Neuroscience

13.4.3.2.10. Respiratory

13.4.3.2.11. Urology

13.4.3.2.12. Others

13.4.4. Kuwait

13.4.4.1. Kuwait Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.4.1.1. Kits and Buffers

13.4.4.1.2. Culture Medium

13.4.4.1.2.1. Natural Media

13.4.4.1.2.1.1. Plasma

13.4.4.1.2.1.2. Serum

13.4.4.1.2.1.3. Lymph

13.4.4.1.2.1.4. Human Placental Cord Serum

13.4.4.1.2.1.5. Amniotic Fluid

13.4.4.1.2.1.6. Others

13.4.4.1.2.2. Artificial Media

13.4.4.1.2.2.1. MEM

13.4.4.1.2.2.2. RPMI

13.4.4.1.2.2.3. PBS

13.4.4.1.2.2.4. DPBS

13.4.4.1.2.2.5. HBSS

13.4.4.1.2.2.6. EBSS

13.4.4.1.2.2.7. Others

13.4.4.1.3. Cryopreservation Media

13.4.4.1.4. Diagnostic Assay

13.4.4.1.5. Others

13.4.4.2. Kuwait Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.4.2.1. Cardiovascular

13.4.4.2.2. Dermatology

13.4.4.2.3. Endocrine and Metabolic

13.4.4.2.4. Gastroenterology

13.4.4.2.5. Hematology and Oncology

13.4.4.2.6. Obstetrics

13.4.4.2.7. Critical Care

13.4.4.2.8. Immunology

13.4.4.2.9. Neuroscience

13.4.4.2.10. Respiratory

13.4.4.2.11. Urology

13.4.4.2.12. Others

13.4.5. South Africa

13.4.5.1. South Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.5.1.1. Kits and Buffers

13.4.5.1.2. Culture Medium

13.4.5.1.2.1. Natural Media

13.4.5.1.2.1.1. Plasma

13.4.5.1.2.1.2. Serum

13.4.5.1.2.1.3. Lymph

13.4.5.1.2.1.4. Human Placental Cord Serum

13.4.5.1.2.1.5. Amniotic Fluid

13.4.5.1.2.1.6. Others

13.4.5.1.2.2. Artificial Media

13.4.5.1.2.2.1. MEM

13.4.5.1.2.2.2. RPMI

13.4.5.1.2.2.3. PBS

13.4.5.1.2.2.4. DPBS

13.4.5.1.2.2.5. HBSS

13.4.5.1.2.2.6. EBSS

13.4.5.1.2.2.7. Others

13.4.5.1.3. Cryopreservation Media

13.4.5.1.4. Diagnostic Assay

13.4.5.1.5. Others

13.4.5.2. South Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.5.2.1. Cardiovascular

13.4.5.2.2. Dermatology

13.4.5.2.3. Endocrine and Metabolic

13.4.5.2.4. Gastroenterology

13.4.5.2.5. Hematology and Oncology

13.4.5.2.6. Obstetrics

13.4.5.2.7. Critical Care

13.4.5.2.8. Immunology

13.4.5.2.9. Neuroscience

13.4.5.2.10. Respiratory

13.4.5.2.11. Urology

13.4.5.2.12. Others

13.4.6. Rest of Middle East & Africa

13.4.6.1. Rest of Middle East & Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

13.4.6.1.1. Kits and Buffers

13.4.6.1.2. Culture Medium

13.4.6.1.2.1. Natural Media

13.4.6.1.2.1.1. Plasma

13.4.6.1.2.1.2. Serum

13.4.6.1.2.1.3. Lymph

13.4.6.1.2.1.4. Human Placental Cord Serum

13.4.6.1.2.1.5. Amniotic Fluid

13.4.6.1.2.1.6. Others

13.4.6.1.2.2. Artificial Media

13.4.6.1.2.2.1. MEM

13.4.6.1.2.2.2. RPMI

13.4.6.1.2.2.3. PBS

13.4.6.1.2.2.4. DPBS

13.4.6.1.2.2.5. HBSS

13.4.6.1.2.2.6. EBSS

13.4.6.1.2.2.7. Others

13.4.6.1.3. Cryopreservation Media

13.4.6.1.4. Diagnostic Assay

13.4.6.1.5. Others

13.4.6.2. Rest of Middle East & Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

13.4.6.2.1. Cardiovascular

13.4.6.2.2. Dermatology

13.4.6.2.3. Endocrine and Metabolic

13.4.6.2.4. Gastroenterology

13.4.6.2.5. Hematology and Oncology

13.4.6.2.6. Obstetrics

13.4.6.2.7. Critical Care

13.4.6.2.8. Immunology

13.4.6.2.9. Neuroscience

13.4.6.2.10. Respiratory

13.4.6.2.11. Urology

13.4.6.2.12. Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Product Type

13.5.3. By Application/Therapeutics

14. Latin America Cell and Gene Therapy Consumables Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn)

14.2. Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

14.2.1. Kits and Buffers

14.2.2. Culture Medium

14.2.2.1. Natural Media

14.2.2.1.1. Plasma

14.2.2.1.2. Serum

14.2.2.1.3. Lymph

14.2.2.1.4. Human Placental Cord Serum

14.2.2.1.5. Amniotic Fluid

14.2.2.1.6. Others

14.2.2.2. Artificial Media

14.2.2.2.1. MEM

14.2.2.2.2. RPMI

14.2.2.2.3. PBS

14.2.2.2.4. DPBS

14.2.2.2.5. HBSS

14.2.2.2.6. EBSS

14.2.2.2.7. Others

14.2.3. Cryopreservation Media

14.2.4. Diagnostic Assay

14.2.5. Others

14.3. Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

14.3.1. Cardiovascular

14.3.2. Dermatology

14.3.3. Endocrine and Metabolic

14.3.4. Gastroenterology

14.3.5. Hematology and Oncology

14.3.6. Obstetrics

14.3.7. Critical Care

14.3.8. Immunology

14.3.9. Neuroscience

14.3.10. Respiratory

14.3.11. Urology

14.3.12. Others

14.4. Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1. Brazil Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

14.4.1.1.1. Kits and Buffers

14.4.1.1.2. Culture Medium

14.4.1.1.2.1. Natural Media

14.4.1.1.2.1.1. Plasma

14.4.1.1.2.1.2. Serum

14.4.1.1.2.1.3. Lymph

14.4.1.1.2.1.4. Human Placental Cord Serum

14.4.1.1.2.1.5. Amniotic Fluid

14.4.1.1.2.1.6. Others

14.4.1.1.2.2. Artificial Media

14.4.1.1.2.2.1. MEM

14.4.1.1.2.2.2. RPMI

14.4.1.1.2.2.3. PBS

14.4.1.1.2.2.4. DPBS

14.4.1.1.2.2.5. HBSS

14.4.1.1.2.2.6. EBSS

14.4.1.1.2.2.7. Others

14.4.1.1.3. Cryopreservation Media

14.4.1.1.4. Diagnostic Assay

14.4.1.1.5. Others

14.4.1.2. Brazil Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

14.4.1.2.1. Cardiovascular

14.4.1.2.2. Dermatology

14.4.1.2.3. Endocrine and Metabolic

14.4.1.2.4. Gastroenterology

14.4.1.2.5. Hematology and Oncology

14.4.1.2.6. Obstetrics

14.4.1.2.7. Critical Care

14.4.1.2.8. Immunology

14.4.1.2.9. Neuroscience

14.4.1.2.10. Respiratory

14.4.1.2.11. Urology

14.4.1.2.12. Others

14.4.2. Argentina

14.4.2.1. Argentina Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

14.4.2.1.1. Kits and Buffers

14.4.2.1.2. Culture Medium

14.4.2.1.2.1. Natural Media

14.4.2.1.2.1.1. Plasma

14.4.2.1.2.1.2. Serum

14.4.2.1.2.1.3. Lymph

14.4.2.1.2.1.4. Human Placental Cord Serum

14.4.2.1.2.1.5. Amniotic Fluid

14.4.2.1.2.1.6. Others

14.4.2.1.2.2. Artificial Media

14.4.2.1.2.2.1. MEM

14.4.2.1.2.2.2. RPMI

14.4.2.1.2.2.3. PBS

14.4.2.1.2.2.4. DPBS

14.4.2.1.2.2.5. HBSS

14.4.2.1.2.2.6. EBSS

14.4.2.1.2.2.7. Others

14.4.2.1.3. Cryopreservation Media

14.4.2.1.4. Diagnostic Assay

14.4.2.1.5. Others

14.4.2.2. Argentina Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

14.4.2.2.1. Cardiovascular

14.4.2.2.2. Dermatology

14.4.2.2.3. Endocrine and Metabolic

14.4.2.2.4. Gastroenterology

14.4.2.2.5. Hematology and Oncology

14.4.2.2.6. Obstetrics

14.4.2.2.7. Critical Care

14.4.2.2.8. Immunology

14.4.2.2.9. Neuroscience

14.4.2.2.10. Respiratory

14.4.2.2.11. Urology

14.4.2.2.12. Others

14.4.3. Rest of Latin America

14.4.3.1. Rest of Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product Type

14.4.3.1.1. Kits and Buffers

14.4.3.1.2. Culture Medium

14.4.3.1.2.1. Natural Media

14.4.3.1.2.1.1. Plasma

14.4.3.1.2.1.2. Serum

14.4.3.1.2.1.3. Lymph

14.4.3.1.2.1.4. Human Placental Cord Serum

14.4.3.1.2.1.5. Amniotic Fluid

14.4.3.1.2.1.6. Others

14.4.3.1.2.2. Artificial Media

14.4.3.1.2.2.1. MEM

14.4.3.1.2.2.2. RPMI

14.4.3.1.2.2.3. PBS

14.4.3.1.2.2.4. DPBS

14.4.3.1.2.2.5. HBSS

14.4.3.1.2.2.6. EBSS

14.4.3.1.2.2.7. Others

14.4.3.1.3. Cryopreservation Media

14.4.3.1.4. Diagnostic Assay

14.4.3.1.5. Others

14.4.3.2. Rest of Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics

14.4.3.2.1. Cardiovascular

14.4.3.2.2. Dermatology

14.4.3.2.3. Endocrine and Metabolic

14.4.3.2.4. Gastroenterology

14.4.3.2.5. Hematology and Oncology

14.4.3.2.6. Obstetrics

14.4.3.2.7. Critical Care

14.4.3.2.8. Immunology

14.4.3.2.9. Neuroscience

14.4.3.2.10. Respiratory

14.4.3.2.11. Urology

14.4.3.2.12. Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Product Type

14.5.3. By Application/Therapeutics

15. Competitive Benchmarking

15.1. Market Share Analysis, 2018

15.2. Global Presence and Growth Strategies

15.2.1. Mergers and Acquisitions

15.2.2. Product Launches

15.2.3. Investments Trends

15.2.4. R&D Initiatives

16. Player Profiles

16.1. Amgen Inc.

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. ATLANTA BIOLOGICALS

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. bluebird bio, Inc.

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. Cook

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. Dendreon Pharmaceuticals LLC.

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. Fibrocell Science, Inc.

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. General Electric

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. Kolon TissueGene, Inc.

16.8.1. Company Details

16.8.2. Company Overview

16.8.3. Product Offerings

16.8.4. Key Developments

16.8.5. Financial Analysis

16.8.6. SWOT Analysis

16.8.7. Business Strategies

16.9. Orchard Therapeutics plc.

16.9.1. Company Details

16.9.2. Company Overview

16.9.3. Product Offerings

16.9.4. Key Developments

16.9.5. Financial Analysis

16.9.6. SWOT Analysis

16.9.7. Business Strategies

16.10. Pfizer, Inc.

16.10.1. Company Details

16.10.2. Company Overview

16.10.3. Product Offerings

16.10.4. Key Developments

16.10.5. Financial Analysis

16.10.6. SWOT Analysis

16.10.7. Business Strategies

16.11. PromoCell GmbH

16.11.1. Company Details

16.11.2. Company Overview

16.11.3. Product Offerings

16.11.4. Key Developments

16.11.5. Financial Analysis

16.11.6. SWOT Analysis

16.11.7. Business Strategies

16.12. RENOVA THERAPEUTICS

16.12.1. Company Details

16.12.2. Company Overview

16.12.3. Product Offerings

16.12.4. Key Developments

16.12.5. Financial Analysis

16.12.6. SWOT Analysis

16.12.7. Business Strategies

16.13. Sibiono GeneTech Co. Ltd.

16.13.1. Company Details

16.13.2. Company Overview

16.13.3. Product Offerings

16.13.4. Key Developments

16.13.5. Financial Analysis

16.13.6. SWOT Analysis

16.13.7. Business Strategies

16.14. Spark Therapeutics, Inc.

16.14.1. Company Details

16.14.2. Company Overview

16.14.3. Product Offerings

16.14.4. Key Developments

16.14.5. Financial Analysis

16.14.6. SWOT Analysis

16.14.7. Business Strategies

16.15. Vericel

16.15.1. Company Details

16.15.2. Company Overview

16.15.3. Product Offerings

16.15.4. Key Developments

16.15.5. Financial Analysis

16.15.6. SWOT Analysis

16.15.7. Business Strategies

16.16. ViroMed Co., Ltd.

16.16.1. Company Details

16.16.2. Company Overview

16.16.3. Product Offerings

16.16.4. Key Developments

16.16.5. Financial Analysis

16.16.6. SWOT Analysis

16.16.7. Business Strategies

16.17. Vitrolife

16.17.1. Company Details

16.17.2. Company Overview

16.17.3. Product Offerings

16.17.4. Key Developments

16.17.5. Financial Analysis

16.17.6. SWOT Analysis

16.17.7. Business Strategies

16.18. Other Market Participants

17. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $3300

Multi users $6600

Global users $7300

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com